Catalyst Therapeutics Pty Ltd is an investment and project management company formed as a joint venture between the Walter and Eliza Hall Institute of Medical Research and SYNthesis Research. Our mission is to create value by accelerating proof-of-concept research and translating biological discoveries into new drug development candidates.
Such translation depends on early stage investment in high-throughput chemical screening and medicinal chemistry, an area where Australian funding continues to be minimal and unpredictable.
Catalyst Therapeutics will focus on medicinal chemistry opportunities that align and synergise with the Walter and Eliza Hall Institute’s biology and clinical interests, and leverage medicinal chemistry expertise of SYNthesis Research and its sister company SYNthesis MedChem.
By supporting and funding projects aligned with the interests of both WEHI and SYNthesis Research, the company will accelerate progress of these programs through the drug discovery and development pathway.
Catalyst therapeutics has an impressive track record with 2 programs already being licensed by a major pharma company during early stages of development.
Company Details
- Founded
- -
- Address
- Parkville,, Melbourne,victoria,australia
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- catalysttx.com.au
- HQ
- Melbourne, Victoria
Catalyst Therapeutics Questions
Catalyst Therapeutics's website is catalysttx.com.au
Catalyst Therapeutics's LinkedIn profile is https://au.linkedin.com/company/catalysttx
Catalyst Therapeutics's industry is
Biotechnology Research
Catalyst Therapeutics's top competitors are
Zucero Therapeutics Ltd,
Cgs Pharma,
Synthesis Bioventures,
Synthesis Research,
Adjutor Healthcare Group,
Catalyst Pharmaceuticals, Inc.,
Tudorrose Consulting Pty Ltd,
Synthesis Med Chem,
Anaxis Pharma,
Oncology One Pty Ltd.
Catalyst Therapeutics's categories are Biotechnology Research
Catalyst Therapeutics's founding year is 2012
